• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

审视糖尿病肥胖症:利用肠道机制治疗 2 型糖尿病和肥胖症。

Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity.

机构信息

Cardiovascular and Metabolic Disease, MedImmune LLC, One MedImmune Way, Gaithersburg, MD 20878, USA.

Cardiovascular and Metabolic Disease, MedImmune Ltd, Granta Park, Cambridge CB21 6GH, UK.

出版信息

Curr Opin Pharmacol. 2017 Dec;37:10-15. doi: 10.1016/j.coph.2017.07.010. Epub 2017 Aug 10.

DOI:10.1016/j.coph.2017.07.010
PMID:28802873
Abstract

Gut hormones have long been understood to regulate food intake and metabolism. Bariatric surgery significantly elevates circulating gut hormone levels and is proven to affect acute remission of type 2 diabetes before any weight loss is observed. Subsequent weight loss is accrued over weeks to months but is sustained into the long term. Hence, there exists great enthusiasm to recapitulate these changes in gut hormones in the form of novel combination drugs for type 2 diabetes and obesity.

摘要

肠道激素一直被认为可以调节食物摄入和新陈代谢。减重手术显著提高了循环肠道激素水平,并被证明可以在观察到体重减轻之前影响 2 型糖尿病的急性缓解。随后的体重减轻会在数周到数月内逐渐增加,但会持续到长期。因此,人们非常希望以新型 2 型糖尿病和肥胖症联合药物的形式重现这些肠道激素变化。

相似文献

1
Gut check on diabesity: leveraging gut mechanisms for the treatment of type 2 diabetes and obesity.审视糖尿病肥胖症:利用肠道机制治疗 2 型糖尿病和肥胖症。
Curr Opin Pharmacol. 2017 Dec;37:10-15. doi: 10.1016/j.coph.2017.07.010. Epub 2017 Aug 10.
2
Gut hormones and appetite regulation.肠道激素与食欲调节。
Curr Opin Endocrinol Diabetes Obes. 2024 Jun 1;31(3):115-121. doi: 10.1097/MED.0000000000000859. Epub 2024 Mar 21.
3
Targeting the Enteroendocrine System for Treatment of Obesity.针对肠内分泌系统治疗肥胖。
Handb Exp Pharmacol. 2022;274:487-513. doi: 10.1007/164_2022_583.
4
The emerging role of the intestine in metabolic diseases.肠道在代谢性疾病中的新作用。
Arch Physiol Biochem. 2011 Jul;117(3):165-76. doi: 10.3109/13813455.2011.578651.
5
Combination gut hormones: prospects and questions for the future of obesity and diabetes therapy.联合肠激素:肥胖和糖尿病治疗未来的前景和问题。
J Endocrinol. 2020 Sep;246(3):R65-R74. doi: 10.1530/JOE-20-0119.
6
Optimization of peptide-based polyagonists for treatment of diabetes and obesity.用于治疗糖尿病和肥胖症的基于肽的多激动剂的优化。
Bioorg Med Chem. 2018 Jun 1;26(10):2873-2881. doi: 10.1016/j.bmc.2017.10.047. Epub 2017 Nov 2.
7
Gut hormones as therapeutic agents in treatment of diabetes and obesity.肠激素作为治疗糖尿病和肥胖症的治疗药物。
Curr Opin Pharmacol. 2013 Dec;13(6):996-1001. doi: 10.1016/j.coph.2013.09.005. Epub 2013 Sep 20.
8
The Importance of the Gastrointestinal Tract in Controlling Food Intake and Regulating Energy Balance.胃肠道在控制食物摄入和调节能量平衡中的重要性。
Gastroenterology. 2017 May;152(7):1707-1717.e2. doi: 10.1053/j.gastro.2017.01.053. Epub 2017 Feb 11.
9
Targeted intestinal delivery of incretin secretagogues-towards new diabetes and obesity therapies.靶向肠内递增进食素分泌剂——新的糖尿病和肥胖症疗法。
Peptides. 2018 Feb;100:68-74. doi: 10.1016/j.peptides.2017.11.008.
10
Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery.肠道激素的肠内分泌分泌在糖尿病、肥胖症和减肥手术后。
Curr Opin Pharmacol. 2013 Dec;13(6):983-8. doi: 10.1016/j.coph.2013.09.014. Epub 2013 Oct 22.

引用本文的文献

1
Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency.机器学习设计出具有增强生物学效力的新型 GCGR/GLP-1R 双重激动剂。
Nat Chem. 2024 Sep;16(9):1436-1444. doi: 10.1038/s41557-024-01532-x. Epub 2024 May 16.
2
Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake.自组装的 GLP-1/胰高血糖素肽纳米原纤维延长了食物摄入的抑制作用。
Front Endocrinol (Lausanne). 2023 Jul 24;14:1217021. doi: 10.3389/fendo.2023.1217021. eCollection 2023.
3
Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives.
临床开发中靶向蛋白质-蛋白质相互作用的治疗性肽:概述、作用机制及展望
Front Mol Biosci. 2021 Jun 14;8:697586. doi: 10.3389/fmolb.2021.697586. eCollection 2021.
4
Therapeutic, Prophylactic, and Functional Use of Probiotics: A Current Perspective.益生菌的治疗、预防及功能应用:当前观点
Front Microbiol. 2020 Sep 11;11:562048. doi: 10.3389/fmicb.2020.562048. eCollection 2020.
5
DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.DR10601,一种新型长效双重胰高血糖素样肽-1 和胰高血糖素受体激动剂,用于治疗肥胖症和 2 型糖尿病。
J Endocrinol Invest. 2020 May;43(5):653-662. doi: 10.1007/s40618-019-01153-z. Epub 2019 Nov 30.